Sunshine Biopharma Inc.

SBFM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001402328

B/C

on the B/C boundary of 370 graded peers in healthcare

rank 142 of 370; percentile 38.3; sampling error 2.5 points; lower is stronger



B/C, the elk



Scoreboard

Profitability	C/D	percentile 61.0
Solvency	C	percentile 44.1
Growth and financing	B	percentile 27.3
Reliability	0.83 AUC	filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets	total assets $30.1M
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	late filer	not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	7 of 14	
Graded from	filings received through Apr 3, 2026	207 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$2.62	2026-10-26; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 3, 2026

life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc. ("Nora Pharma"), a Canadian corporation, through which we currently have 71 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. ("Sunshine Canada"), a Canadian corporation which develops development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease of rights to pharmaceutical products for sale, currently in Canada and ultimately around the world.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.0						
Gross profitability	40.7%	32.3%		31.4	369	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.1%)	(6.6%)	75.6	805	2025-12-31
Gross margin stability, five years	6.2 pts	2.8 pts	76.1	242	2025-12-31
Solvency, sleeve percentile 44.1					
Twelve-month failure probability	not computable	0.07%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(1.63)	(0.33)	44.2	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	4.17x	2.94x	44.0	832	2025-12-31
Growth and financing, sleeve percentile 27.3					
Revenue growth, three-year compound	102.9%	10.1%	5.0	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	0.9%	2.1%	49.6	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
137	Biocryst Pharmaceuticals Inc. (BCRX)	36.9	B	fortress balance sheet
138	LifeMD, Inc. (LFMD)	37.3	B	late filer
139	LifeMD, Inc. (LFMDP)	37.3	B	late filer
140	Sanuwave Health, Inc. (SNWV)	37.7	B/C	
141	Collegium Pharmaceutical, Inc. (COLL)	37.9	B/C	fortress balance sheet
142	Sunshine Biopharma Inc. (SBFM)	38.3	B/C	late filer
143	Sunshine Biopharma Inc. (SBFMW)	38.3	B/C	late filer
144	Lakeland Industries Inc. (LAKE)	38.8	B/C	late filer, fortress balance sheet
145	Artivion, Inc. (AORT)	39.0	B/C	
146	LifeStance Health Group, Inc. (LFST)	39.3	B/C	
147	UroGen Pharma Ltd. (URGN)	39.6	B/C	short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(92.5%)	7.7%	1
Distance from 52-week high	(86.5%)	(31.2%)	6
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(2.80)	(0.14)	1

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	75 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$199,278

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$12.3M	2025-12-31	2026-04-03	10-K	26-002644
2	assets	us-gaap:Assets	$30.1M	2025-12-31	2026-04-03	10-K	26-002644
3	net income	us-gaap:NetIncomeLoss	-$6.0M	2025-12-31	2026-04-03	10-K	26-002644
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.3M	2025-12-31	2026-04-03	10-K	26-002644
5	assets	us-gaap:Assets	$30.6M	2024-12-31	2026-04-03	10-K	26-002644
6	revenue	us-gaap:Revenues	$36.3M	2025-12-31	2026-04-03	10-K	26-002644
7	gross profit	us-gaap:GrossProfit	$10.7M	2024-12-31	2026-04-03	10-K	26-002644
8	revenue	us-gaap:Revenues	$34.9M	2024-12-31	2026-04-03	10-K	26-002644
9	gross profit	us-gaap:GrossProfit	$8.3M	2023-12-31	2025-04-01	10-K	25-002184
10	revenue	us-gaap:Revenues	$24.1M	2023-12-31	2025-04-01	10-K	25-002184
11	gross profit	us-gaap:GrossProfit	$1.7M	2022-12-31	2024-03-28	10-K	24-001818
12	revenue	us-gaap:Revenues	$4.3M	2022-12-31	2024-03-28	10-K	24-001818
13	gross profit	us-gaap:GrossProfit	$110,596	2021-12-31	2023-04-04	10-K	23-002128
14	revenue	us-gaap:Revenues	$228,426	2021-12-31	2023-04-04	10-K	23-002128
15	current assets	us-gaap:AssetsCurrent	$26.9M	2025-12-31	2026-04-03	10-K	26-002644
16	current liabilities	us-gaap:LiabilitiesCurrent	$6.4M	2025-12-31	2026-04-03	10-K	26-002644
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$75.0M	2025-12-31	2026-04-03	10-K	26-002644
18	operating income	us-gaap:OperatingIncomeLoss	-$6.2M	2025-12-31	2026-04-03	10-K	26-002644

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$23.0M	2025-12-31	2026-04-03	10-K	26-002644
20	liabilities	us-gaap:Liabilities	$7.0M	2025-12-31	2026-04-03	10-K	26-002644
21	operating income	us-gaap:OperatingIncomeLoss	-$4.8M	2023-12-31	2025-04-01	10-K	25-002184
22	interest expense	us-gaap:InterestExpense	$137,308	2023-12-31	2024-03-28	10-K	24-001818
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$174,491	2025-12-31	2026-04-03	10-K	26-002644
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.5M	2024-12-31	2026-04-03	10-K	26-002644
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.7M	2024-12-31	2026-04-03	10-K	26-002644
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.8M	2023-12-31	2025-04-01	10-K	25-002184
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$82,251	2023-12-31	2025-04-01	10-K	25-002184
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.2M	2022-12-31	2024-03-28	10-K	24-001818
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$193,982	2022-12-31	2024-03-28	10-K	24-001818
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$332,070	2025-12-31	2026-04-03	10-K	26-002644
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$6.0M	2025-12-31	2026-04-03	10-K	26-002644
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$21,609	2025-12-31	2026-04-03	10-K	26-002644
33	current assets	us-gaap:AssetsCurrent	$26.0M	2024-12-31	2026-04-03	10-K	26-002644
34	current liabilities	us-gaap:LiabilitiesCurrent	$6.3M	2024-12-31	2026-04-03	10-K	26-002644
35	assets	us-gaap:Assets	$27.3M	2023-12-31	2025-04-01	10-K	25-002184
36	assets	us-gaap:Assets	$29.2M	2022-12-31	2024-03-28	10-K	24-001818

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.